Last reviewed · How we verify
Stavanger University Hospital IBD Study - a Cross Sectional Longitudinal Study on Patients Treated With Biologics (SUSI-CS)
In this cross sectional and longitudinal study, patients with inflammatory bowel disease on biological treatment with infliximab or adalimumab will be included. After inclusion, the dosage of their existing biological therapy will be adjusted following regular trough-level and antibody-level monitoring, according to a treatment algorithm. Disease activity markers, fatigue and QoL will be assessed during the study. The hypothesis is that therapeutic drug monitoring may improve clinical disease outcome after one year of follow-up.
Details
| Lead sponsor | Helse Stavanger HF |
|---|---|
| Status | UNKNOWN |
| Enrolment | 210 |
| Start date | 2014-04 |
| Completion | 2024-12 |
Conditions
- Inflammatory Bowel Disease
Primary outcomes
- Clinical remission rate — One Year
Harvey Bradshaw Index \<5 Partial Mayo score \<=2
Countries
Norway